Clinical trial / 2016
Mucuna pruriens extract provided less clinical benefit and a 3.5-fold lower median AUC than levodopa combined with a dopa-decarboxylase inhibitor in PD patients.
Researchers analyzed 25 Mucuna pruriens (MP) samples and tested levodopa pharmacokinetics and motor response in four Parkinson's disease patients comparing MP to levodopa plus a dopa-decarboxylase inhibitor (LD+DDCI). Median levodopa concentration was 5.29% in dried seeds and 5.3% in roasted powder, while boiling reduced levodopa content by up to 70%. In patients, MP extract at a similar levodopa dose provided less clinical benefit and yielded a 3.5-fold lower median AUC compared to LD+DDCI. The authors conclude MP may offer clinical benefit only when its levodopa content is at least 3.5-fold higher than standard LD+DDCI formulations.
- Study type
- Comparative laboratory and pharmacokinetic study
- Who was studied
- 4 Parkinson's disease patients (and 25 Mucuna pruriens samples)
- What was measured
- Levodopa concentration, pharmacokinetics (AUC), and motor response
THE PAPER
Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Cassani E, Cilia R, Laguna J, Barichella M, Contin M, Cereda E, Isaias IU, Sparvoli F, Akpalu A, Budu KO, Scarpa MT, Pezzoli G. J Neurol Sci, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.